Nasdaq ardx.

Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...Apr 24, 2023 · Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ... Feb 15, 2023 · In the latest trading session, Ardelyx (ARDX) closed at $3.02, marking a -1.63% move from the previous day. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added ... Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx’s financial performance into perspective. NASDAQ: ARDX. $4.76. …The restructuring drive implemented on August 02 is intended “to reduce operating costs and better align the Company’s workforce with the needs of its business,” Ardelyx (NASDAQ:ARDX) said ...

Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.

Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript October 31, 2023 Ardelyx, Inc. beats earnings expectations. Reported EPS is $0.02909, expectations were $-0.11. Operator: Good day and ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ... Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago.Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ...

WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

WALTHAM, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx ( NASDAQ: ARDX) shares spiked ~10% on Tuesday after the developer of gastrointestinal and cardiorenal therapies soundly beat Wall Street expectations with its Q3 2023 financials, thanks ...Nov 16, 2023 · Ardelyx Inc (NASDAQ:ARDX) showed a performance of -1.41% in past 30-days. Number of shares sold short was 36.47 million shares which calculate 4.09 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $9.64 to the stock, which implies a rise of 59.96% to its recent value today. Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.

WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...ARDX STOCK Price - Ardelyx Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.Ardelyx (NASDAQ: ARDX) stock is climbing today after the U.S. Food and Drug Administration ( FDA) approved the firm’s treatment for excessive phosphate levels in kidney disease patients. Shares ...Find the latest Institutional Holdings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Sep 28, 2023 · WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...

Discover historical prices for ARDX stock on Yahoo Finance. View daily, weekly or monthly format back to when Ardelyx, Inc. stock was issued.Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.Plug Power, Inc. Common Stock. $9.46 -1.29 -12.00%. Ardelyx, Inc. Common Stock (ARDX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and ... 22 thg 11, 2023 ... Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, surging 15% in the last week alone · Unless you borrow money to ...WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Xphozah …WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, …Ardelyx, Inc. ( NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...

NasdaqGM:ARDX Insider Trading Volume June 12th 2021 Ardelyx is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Find real-time ARDX - Ardelyx Inc stock quotes, company profile, news and forecasts from CNN Business. ... Ardelyx Inc (NASDAQ:ARDX) Real-Time Quotes. 4.55. BATS BZX Real-Time Price. As of 10:35am ETArdelyx ( NASDAQ: ARDX) shares spiked ~10% on Tuesday after the developer of gastrointestinal and cardiorenal therapies soundly beat Wall Street expectations with its Q3 2023 financials, thanks ...Ardelyx Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ARDX updated stock price target summary.WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...May 17, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ... Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock.Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F …designer491. Shares of Ardelyx ( NASDAQ: ARDX) were down 17% in afternoon trading Wednesday ahead of an expected FDA decision on its kidney disease treatment candidate Xphozah and amid a market ...After Hours Volume: 64.24K. Close. Chg. Chg %. $4.3300. 0.3000. 7.44%. Ardelyx Inc. advanced stock charts by MarketWatch. View ARDX historial stock data and compare to other stocks and exchanges.Ardelyx (ARDX) Company Description: Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases.

Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ...The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...Ardelyx (NASDAQ: ARDX) stock is climbing today after the U.S. Food and Drug Administration ( FDA) approved the firm’s treatment for excessive phosphate levels in kidney disease patients. Shares ...WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Instagram:https://instagram. best stocks to buy now on cash applarge cap companiesnyse aap compareloans for fixer uppers WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. blocks.tradegtbc stock A high-level overview of Ardelyx, Inc. (ARDX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call and put options information of stocks. Financial analysts and ... penny picks WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Factors of Influence in 2019, Key Indicators and Opportunity within Cousins Properties, Versum Materials, Meritor, Ardelyx, Molecular Templates, and Talend S.A — New Research Emphasizes Economic ...08:06 AM ET 12/04/2023. Dow Jones futures fell modestly early Monday, along with S&P 500 futures and Nasdaq futures. The stock market rally briefly hinted it might be ready …